Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00745264
Other study ID # CL-033-I-04
Secondary ID
Status Completed
Phase Phase 1
First received September 2, 2008
Last updated March 19, 2009
Start date October 2007
Est. completion date May 2008

Study information

Verified date March 2009
Source IDEA AG
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

- Comparison of the plasma PK after single use of 100 mg ketoprofen from Diractin®. 50 mg applied on 2 major joints to

- 400 mg ketoprofen from Diractin® (100 mg applied to 4 joints - overexposure)

- 100 mg and 400 mg ketoprofen from Diractin® used concomitant with heat application

- 100 mg and 400 mg ketoprofen from Diractin® used concomitant with moderate exercise


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date May 2008
Est. primary completion date March 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- All of the following criteria have to be met to include a subject in the study:

- Understands nature and provision of the study

- Have been informed about the study by the investigator and gave signed and dated informed consent prior to participation

- Male and female subjects

- Age 18-55 years

- Subjects in good health as determined by the Investigator

- Woman of childbearing potential using reliable methods of contraception with a low failure rate (i.e. less than 1% per year), e.g. implants, injectables, combined oral contraceptives, reliable intrauterine-devices, vasectomised/ infertile partner or surgically sterile (uterus removed or both tubes tied) or postmenopausal (at least 2 years without periods)

Exclusion Criteria:

- 4.2.1 General Exclusion Criteria

- Investigator or any other team member involved directly or indirectly in the conduct of the clinical trial

- Subjects who are inmates of psychiatric wards, prisons, or other state institutions

- Participation in another clinical trial within the last 30 days

- Not willing to refrain from exposing target areas after treatment to excessive ultraviolet light (solar radiation or solarium)

- Pregnancy or lactation

4.2.2 Medical History Related Exclusion Criteria

- Known hypersensitivity or allergy (including photoallergy) to NSAID´s including ketoprofen, and ingredients used in pharmaceutical products

- Alcohol or drug abuse

- Malignancy within the past 2 years

- Skin lesions, dermatological diseases or tattoo in the treatment area

- Major surgery 3 months before enrolment

- Impaired haematopoesis and coagulation

- Gastric and duodenal ulcer and gastrointestinal bleedings

- Systemic lupus erythematodes, mixed connective tissue disease

- Major heart disease / uncontrolled hypertension

- Hepatic failure with ALT and/or AST > 2.0 ULN

- Renal failure with serum creatinine levels > 1.5 milligrams/deciliter (mg/dL)

- Varicosis, thrombophlebitis and other vascular disorders of the lower extremities

- Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the musculo-sceletal system of the lower limbs

- HIV - Infection

- Blood donation one (1) month before screening and during study

- Hepatitis B and C

- Asthma bronchiale

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Drug:
Diractin
100 mg Ketoprofen to 2 joints
Diractin
400 mg ketoprofen to 4 joints
Diractin
100 and 400 mg Ketoprofen used concomittant with heat
Diractin
100 and 400 mg Ketoprofen concomittant with moderate exercise

Locations

Country Name City State
Germany X-pert Med GmbH Jena
Germany ClinPharm Interantional GmbH Leipzig

Sponsors (1)

Lead Sponsor Collaborator
IDEA AG

Country where clinical trial is conducted

Germany, 

See also
  Status Clinical Trial Phase
Completed NCT04531150 - Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects Phase 1
Completed NCT03437265 - A Pharmacokinetic Study of PLENVU® in Healthy Subjects Phase 1
Completed NCT03979989 - Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol) Phase 1
Completed NCT00743912 - Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers Phase 1
Not yet recruiting NCT05367011 - Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU
Completed NCT06126562 - A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects Phase 1
Completed NCT03344627 - Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients N/A
Completed NCT01082796 - Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects N/A
Terminated NCT02696954 - Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects Phase 1/Phase 2
Recruiting NCT03714568 - Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants. Phase 1
Recruiting NCT04080895 - Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects Phase 1
Active, not recruiting NCT04735913 - Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults Early Phase 1
Completed NCT03011996 - To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration Phase 1
Completed NCT00681395 - Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium Phase 1
Completed NCT04617509 - A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 Phase 1
Terminated NCT03059511 - Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants Phase 1
Withdrawn NCT05938608 - A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body Phase 1
Completed NCT01091532 - A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects. Phase 1
Completed NCT03951402 - Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women Phase 1
Completed NCT03882762 - A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol Phase 1